Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Inventory (2016 - 2025)

Guided Therapeutics' Change in Inventory history spans 14 years, with the latest figure at -$12000.0 for Q3 2025.

  • For Q3 2025, Change in Inventory fell 400.0% year-over-year to -$12000.0; the TTM value through Sep 2025 reached -$53000.0, down 381.82%, while the annual FY2024 figure was $1000.0, 98.81% down from the prior year.
  • Change in Inventory for Q3 2025 was -$12000.0 at Guided Therapeutics, up from -$38000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $74000.0 in Q3 2023 and bottomed at -$47000.0 in Q4 2021.
  • The 5-year median for Change in Inventory is $0.0 (2021), against an average of $3750.0.
  • The largest YoY upside for Change in Inventory was 6000.0% in 2023 against a maximum downside of 3700.0% in 2023.
  • A 5-year view of Change in Inventory shows it stood at -$47000.0 in 2021, then surged by 170.21% to $33000.0 in 2022, then crashed by 145.45% to -$15000.0 in 2023, then surged by 80.0% to -$3000.0 in 2024, then plummeted by 300.0% to -$12000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Change in Inventory are -$12000.0 (Q3 2025), -$38000.0 (Q2 2025), and -$3000.0 (Q4 2024).